Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Investments (2019 - 2025)

Historic Long-Term Investments for BridgeBio Pharma (BBIO) over the last 5 years, with Q3 2025 value amounting to $92.2 million.

  • BridgeBio Pharma's Long-Term Investments fell 4255.41% to $92.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.2 million, marking a year-over-year decrease of 4255.41%. This contributed to the annual value of $143.7 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, BridgeBio Pharma's Long-Term Investments stood at $92.2 million, which was down 4255.41% from $108.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Long-Term Investments ranged from a high of $160.4 million in Q3 2024 and a low of $60.7 million during Q2 2021
  • Over the past 3 years, BridgeBio Pharma's median Long-Term Investments value was $112.5 million (recorded in 2024), while the average stood at $111.6 million.
  • In the last 5 years, BridgeBio Pharma's Long-Term Investments soared by 25416.63% in 2021 and then tumbled by 4255.41% in 2025.
  • Quarter analysis of 3 years shows BridgeBio Pharma's Long-Term Investments stood at $60.7 million in 2021, then soared by 136.86% to $143.7 million in 2024, then crashed by 35.88% to $92.2 million in 2025.
  • Its Long-Term Investments stands at $92.2 million for Q3 2025, versus $108.0 million for Q2 2025 and $128.2 million for Q1 2025.